| Poly (ADP-Ribose) polymerase inhibitors in pancreatic cancer: a new treatment paradigms and future implications M Gupta, R Iyer, C Fountzilas Cancers 11 (12), 1980, 2019 | 34 | 2019 |
| A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma C Fountzilas, M Gupta, S Lee, S Krishnamurthi, B Estfan, K Wang, ... British journal of cancer 122 (7), 963-970, 2020 | 27 | 2020 |
| Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer Y Abdou, M Gupta, M Asaoka, K Attwood, O Mateusz, S Gandhi, K Takabe Scientific Reports 12 (1), 13377, 2022 | 24 | 2022 |
| Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature M Gupta, C Sherrow, ME Krone, EM Blais, MJ Pishvaian, EF Petricoin, ... Journal of the National Comprehensive Cancer Network 19 (1), 10-15, 2021 | 20 | 2021 |
| Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy A Singh, N Mencia-Trinchant, EA Griffiths, A Altahan, M Swaminathan, ... JCO Precision Oncology 6, e2100309, 2022 | 18 | 2022 |
| Exploring the role of survivin in neuroendocrine neoplasms A Hanif, S Lee, M Gupta, A Chander, ED Kannisto, A Punnanitinont, ... Oncotarget 11 (23), 2246, 2020 | 15 | 2020 |
| Health-related quality of life (HRQoL) in neuroendocrine tumors: a systematic review R Gosain, M Gupta, AM Roy, J Strosberg, KM Glaser, R Iyer Cancers 14 (6), 1428, 2022 | 12 | 2022 |
| Pavement subgrade stabilisation using refractory castables: minimisation of layer thickness S Anand, A Gaur, M Gupta, MP Deori Road Materials and Pavement Design 23 (11), 2669-2683, 2022 | 5 | 2022 |
| The impact of neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment (TME) in patients with colorectal cancer with liver metastases (CRCLM). M Gupta, T Smith, W Bshara, J Terhune, K Attwood, S Mukherjee, RV Iyer, ... Journal of Clinical Oncology 39 (3_suppl), 124-124, 2021 | 2 | 2021 |
| Exploring Plasma-Derived Exosomes (PDEs) as a Response Biomarker in Neuroendocrine Tumors (NETs) M Gupta, O Maguire, M Bapardekar, K Attwood, H Minderman, R Iyer PANCREAS 50 (3), 442-442, 2021 | 1 | 2021 |
| Geographic and demographic disparities in breast cancer outcomes: A population-based study. R Gosain, Y Abdou, M Gupta, M Sarma, A Groman, S Gandhi Journal of Clinical Oncology 38 (15_suppl), 7028-7028, 2020 | 1 | 2020 |
| Abstract P2-09-09: Breast cancer arising on the left side is biologically more aggressive and has worse outcomes compared to the right side Y Abdou, M Gupta, M Asaoka, K Attwood, O Mateusz, S Gandhi, K Takabe Cancer Research 80 (4_Supplement), P2-09-09-P2-09-09, 2020 | 1 | 2020 |
| Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of … M Gupta, M Choi, RA Ramirez, K Attwood, S Mukherjee, RV Iyer Journal of Clinical Oncology 38 (4_suppl), TPS636-TPS636, 2020 | 1 | 2020 |
| Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma C Fountzilas, SA Velasco, W Bshara, CM LeVea, M Gupta, W Ji, A George, ... Journal of Gastrointestinal Oncology 14 (5), 2192, 2023 | | 2023 |
| 646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS … A Hendifar, DR Spigel, A Basu-Mallick, D Richards, M Fakih, J Boles, ... Annals of Oncology 34, S454-S455, 2023 | | 2023 |
| Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO). PM Boland, S Mukherjee, I Imanirad, N Vijayvergia, SD Cohen, M Gupta, ... Journal of Clinical Oncology 41 (16_suppl), 3590-3590, 2023 | | 2023 |
| Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals. M Gupta, OS Akhtar, B Bahl, A Mier-Hicks, K Attwood, K Catalfamo, ... Journal of Clinical Oncology 40 (16_suppl), 6519-6519, 2022 | | 2022 |
| Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. R Gosain, M Gupta, AM Roy, J Strosberg, KM Glaser, R Iyer Cancers 14 (6), 1428-1428, 2022 | | 2022 |
| Mutant PPM1D and TP53 populate the hematopoietic compartment after peptide receptor radionuclide therapy (PRRT) exposure. A Singh, N Mencia-Trinchant, EA Griffiths, M Gupta, M Gravina, ... Journal of Clinical Oncology 39 (15_suppl), 10605-10605, 2021 | | 2021 |
| Abstract PS7-29: Racial disparities in breast cancer outcomes: A SEER population based study M Gupta, R Gosain, M Sarma, S Perimbeti, K Attwood, W Ji, S Gandhi, ... Cancer Research 81 (4_Supplement), PS7-29-PS7-29, 2021 | | 2021 |
